SCHEMBL30970909

SCHEMBL30970909

O=Cc1cnn(-c2ccccn2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH2 Q6NS38 1/20 0.56
EGLN1 Q9GZT9 1/20 0.56
MTOR P42345 1/20 0.54
GRM4 Q14833 1/20 0.47
GRM5 P41594 1/20 0.45
DRD2 P14416 2/20 0.43
DRD4 P21917 2/20 0.43
DRD3 P35462 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 1/20 0.41
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
EP300 Q09472 1/20 0.37
KAT2B Q92831 1/20 0.37
MAPK1 P28482 1/20 0.37
KCNJ1 P48048 1/20 0.36
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3146717 1.00 ALKBH2 (0.56) ALKBH2EGLN1MTORGRM4GRM5
SCHEMBL30638212 0.79 MTOR (0.37) ALKBH2EGLN1MTORDRD2DRD4
SCHEMBL27905763 0.79 KDM4E (0.37) ALKBH2EGLN1MTORSMN1; SMN2NPC1
SCHEMBL18585844 0.76 ALDH1A1 (0.48) ALKBH2EGLN1MTORSMN1; SMN2MAPT
SCHEMBL30445068 0.76 MTOR (0.35) ALKBH2EGLN1MTORGRM4SMN1; SMN2
SCHEMBL20168528 0.76 MTOR (0.35) ALKBH2EGLN1MTORGRM4SMN1; SMN2
SCHEMBL16648845 0.75 KCNJ1 (0.42) ALKBH2EGLN1MTORSMN1; SMN2NPC1
SCHEMBL70114 0.75 NPC1 (0.63) ALKBH2MTORGRM4SMN1; SMN2MAPT
SCHEMBL20574129 0.74 GRIN2D (0.34) ALKBH2EGLN1MTORGRM4SMN1; SMN2
SCHEMBL18586335 0.74 RECQL (0.41) MTORSMN1; SMN2MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171437-A1 (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA AGIOS PHARMACEUTICALS, INC. 2025-05-29 US disclosed
CN-112368279-B Novel compounds as mTOR inhibitors and uses thereof 医药生命融合研究团 2024-05-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171437-A1 (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA PAH, BCKDK, PKM ALKBH2 732/4885EGLN1 77/4885MTOR 1074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.